176 related articles for article (PubMed ID: 9788621)
1. Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes.
Ganss R; Hanahan D
Cancer Res; 1998 Oct; 58(20):4673-81. PubMed ID: 9788621
[TBL] [Abstract][Full Text] [Related]
2. Breaking immunologic ignorance to an antigenic peptide of simian virus 40 large T antigen.
Soldevila G; Geiger T; Flavell RA
J Immunol; 1995 Dec; 155(12):5590-600. PubMed ID: 7499842
[TBL] [Abstract][Full Text] [Related]
3. T cells are responsive to the simian virus 40 large tumor antigen transgenically expressed in pancreatic islets.
Geiger T; Soldevila G; Flavell RA
J Immunol; 1993 Dec; 151(12):7030-7. PubMed ID: 8258707
[TBL] [Abstract][Full Text] [Related]
4. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
5. CD4+ T lymphocytes play a critical role in antibody production and tumor immunity against simian virus 40 large tumor antigen.
Kennedy RC; Shearer MH; Watts AM; Bright RK
Cancer Res; 2003 Mar; 63(5):1040-5. PubMed ID: 12615720
[TBL] [Abstract][Full Text] [Related]
6. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
Neeley YC; Arredouani MS; Hollenbeck B; Eng MH; Rubin MA; Sanda MG
Prostate; 2008 May; 68(7):715-27. PubMed ID: 18302222
[TBL] [Abstract][Full Text] [Related]
7. Arming tumor-reactive T cells with costimulator B7-1 enhances therapeutic efficacy of the T cells.
Zheng G; Liu S; Wang P; Xu Y; Chen A
Cancer Res; 2006 Jul; 66(13):6793-9. PubMed ID: 16818656
[TBL] [Abstract][Full Text] [Related]
8. Efficient eradication of subcutaneous but not of autochthonous gastric tumors by adoptive T cell transfer in an SV40 T antigen mouse model.
Bourquin C; von der Borch P; Zoglmeier C; Anz D; Sandholzer N; Suhartha N; Wurzenberger C; Denzel A; Kammerer R; Zimmermann W; Endres S
J Immunol; 2010 Aug; 185(4):2580-8. PubMed ID: 20644173
[TBL] [Abstract][Full Text] [Related]
9. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.
Chin CS; Miller CH; Graham L; Parviz M; Zacur S; Patel B; Duong A; Bear HD
Int Immunol; 2004 Sep; 16(9):1283-94. PubMed ID: 15262898
[TBL] [Abstract][Full Text] [Related]
10. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
[TBL] [Abstract][Full Text] [Related]
11. Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.
Utermöhlen O; Schulze-Garg C; Warnecke G; Gugel R; Löhler J; Deppert W
J Virol; 2001 Nov; 75(22):10593-602. PubMed ID: 11602701
[TBL] [Abstract][Full Text] [Related]
12. Adoptively transferred tumor-specific T cells stimulated ex vivo using herpes simplex virus amplicons encoding 4-1BBL persist in the host and show antitumor activity in vivo.
Yi KH; Nechushtan H; Bowers WJ; Walker GR; Zhang Y; Pham DG; Podack ER; Federoff HJ; Tolba KA; Rosenblatt JD
Cancer Res; 2007 Oct; 67(20):10027-37. PubMed ID: 17942937
[TBL] [Abstract][Full Text] [Related]
13. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM
Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874
[TBL] [Abstract][Full Text] [Related]
14. Active CD4+ helper T cells directly stimulate CD8+ cytotoxic T lymphocyte responses in wild-type and MHC II gene knockout C57BL/6 mice and transgenic RIP-mOVA mice expressing islet beta-cell ovalbumin antigen leading to diabetes.
Ye Z; Ahmed KA; Hao S; Zhang X; Xie Y; Munegowda MA; Meng Q; Chibbar R; Xiang J
Autoimmunity; 2008 Nov; 41(7):501-11. PubMed ID: 18855194
[TBL] [Abstract][Full Text] [Related]
15. Targeted liposomal delivery of TLR9 ligands activates spontaneous antitumor immunity in an autochthonous cancer model.
Hamzah J; Altin JG; Herringson T; Parish CR; Hämmerling GJ; O'Donoghue H; Ganss R
J Immunol; 2009 Jul; 183(2):1091-8. PubMed ID: 19561111
[TBL] [Abstract][Full Text] [Related]
16. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
[TBL] [Abstract][Full Text] [Related]
17. Experimental autoimmune diabetes: a new tool to study mechanisms and consequences of insulin-specific autoimmunity.
Rajasalu T; Barth C; Spyrantis A; Durinovic-Belló I; Uibo R; Schirmbeck R; Boehm BO; Karges W
Ann N Y Acad Sci; 2004 Dec; 1037():208-15. PubMed ID: 15699519
[TBL] [Abstract][Full Text] [Related]
18. CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction.
Garbi N; Arnold B; Gordon S; Hämmerling GJ; Ganss R
J Immunol; 2004 May; 172(10):5861-9. PubMed ID: 15128765
[TBL] [Abstract][Full Text] [Related]
19. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
Huang H; Li F; Gordon JR; Xiang J
Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823
[TBL] [Abstract][Full Text] [Related]
20. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication.
Ganss R; Ryschich E; Klar E; Arnold B; Hämmerling GJ
Cancer Res; 2002 Mar; 62(5):1462-70. PubMed ID: 11888921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
